drugset / Trial / NCT01529138

Study of Axitinib and Temsirolimus in Solid Tumors

NCT01529138

Phase 1 Completed 13 enrolled Emory University Pfizer · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is being done to determine the highest safe dose of the combination of temsirolimus and axitinib; to learn the side effects when these drugs are given together; and to determine how the patient's disease responds to treatment. The combination of the drugs temsirolimus and axitinib has not been studied before so it is unknown whether this treatment will have any benefit in the patient's cancer. Temsirolimus is commercially available and approved for treatment of some types of kidney cancer. Axitinib has been tested in several diseases but it is not yet commercially available for the treatment of any cancer in the United States. The combination of temsirolimus and axitinib is not approved for treatment of any cancer outside of a clinical trial.

Timeline

Start
2011-10
Primary completion
2014-03
Completion
2014-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Axitinib Small molecule Oral
Subject Temsirolimus Small molecule

Indications